These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37485781)

  • 1. Correction to "Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan".
    Thorac Cancer; 2023 Sep; 14(25):2631. PubMed ID: 37485781
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.
    Shimokawa M; Kanazu M; Saito R; Mori M; Tamura A; Okano Y; Fujita Y; Endo T; Motegi M; Takata S; Kita T; Sukoh N; Mizuki F; Takenoyama M; Atagi S
    Thorac Cancer; 2023 Jun; 14(17):1597-1605. PubMed ID: 37073452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
    Wang XQ; Liu J; Lin HS; Hou W
    Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study.
    Hisakane K; Tozuka T; Takahashi S; Taniuchi N; Nishijima N; Atsumi K; Okano T; Seike M; Hirose T
    Thorac Cancer; 2023 Jul; 14(21):2069-2076. PubMed ID: 37290434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019.
    Goto Y; Kawamura K; Fukuhara T; Namba Y; Aoe K; Shukuya T; Tsuda T; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Nokihara H
    Curr Ther Res Clin Exp; 2023; 99():100712. PubMed ID: 37519418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).
    Takeda K; Hida T; Sato T; Ando M; Seto T; Satouchi M; Ichinose Y; Katakami N; Yamamoto N; Kudoh S; Sasaki J; Matsui K; Takayama K; Kashii T; Iwamoto Y; Sawa T; Okamoto I; Kurata T; Nakagawa K; Fukuoka M
    J Clin Oncol; 2010 Feb; 28(5):753-60. PubMed ID: 20038730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.
    Nasu I; Kondo M; Uozumi R; Takada S; Nawata S; Iihara H; Okumura Y; Takemoto M; Mino K; Sasaki T; Hirose C; Aomori T; Shimano R; Maeno K; Oizumi S; Kusumoto S; Ohno Y; Ikemura S; Takai D; Hara A; Kawazoe H; Nakamura T
    J Cancer; 2023; 14(5):676-688. PubMed ID: 37056385
    [No Abstract]   [Full Text] [Related]  

  • 9. Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study.
    Wang X; Wang T; Chu Y; Liu J; Yi C; Yu X; Wang Y; Zheng T; Cao F; Qu L; Yu B; Liu H; Ding F; Wang S; Wang X; Hao J; Wang X
    Front Oncol; 2023; 13():1089234. PubMed ID: 37007066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan.
    Kanazu M; Shimokawa M; Saito R; Mori M; Tamura A; Okano Y; Fujita Y; Endo T; Motegi M; Takata S; Kita T; Sukoh N; Takenoyama M; Atagi S
    J Geriatr Oncol; 2022 Nov; 13(8):1216-1222. PubMed ID: 36008273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
    Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
    Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
    Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Babineaux S; Morissette N; Thompson D
    Value Health; 2009 Jun; 12(4):481-8. PubMed ID: 18980633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
    Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.
    Davidoff AJ; Tang M; Seal B; Edelman MJ
    J Clin Oncol; 2010 May; 28(13):2191-7. PubMed ID: 20351329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.
    Paik SS; Hwang IK; Park MJ; Lee SH
    Tuberc Respir Dis (Seoul); 2018 Apr; 81(2):148-155. PubMed ID: 29527843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.
    Yamane Y; Shiono A; Ishii Y; Isobe K; Miyauchi E; Kishi K; Nishino M; Sugawara S; Ko R; Koyama N; Yabuki Y; Kobayashi K
    Jpn J Clin Oncol; 2016 Dec; 46(12):1135-1142. PubMed ID: 27655904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.